MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/bjd/ljac007

Медицинская библиотека · The British journal of dermatology · 2023

B-cell and complement signature in severe hidradenitis suppurativa that does not respond to adalimumab.

Hambly Roisin, Gatault Solene, Smith Conor M, Iglesias-Martinez Luis F, Kearns Sean, Rea Helen, Marasigan Vivien, Lynam-Loane Kate, Kirthi Shivashini, Hughes Rosalind, Fletcher Jean M, Kolch Walter, Kirby Brian

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder with significant morbidity. The pathogenesis remains incompletely understood although immune dysregulation plays an important role. It is challenging to treat and approximately 50% of patients respond clinically to adalimumab, the only licensed treatment.

OBJECTIVES

To examine differences between lesional and nonlesional HS skin at baseline using bulk RNA sequencing, and to compare the transcriptome in the skin before and after 12 weeks of treatment with adalimumab. To examine transcriptomic differences between adalimumab responders and nonresponders using Hidradenitis Suppurativa Clinical Response and the International Hidradenitis Suppurativa Severity Score System (IHS4); and to compare transcriptomic differences based on disease severity (Hurley stage and IHS4).

METHODS

We completed bulk RNA sequencing on lesional and nonlesional skin samples of patients before and after 12 weeks of treatment with adalimumab.

RESULTS

Baseline differentially expressed genes and pathways between lesional and nonlesional skin highlighted chemokines and antimicrobial peptides produced by keratinocytes; B-cell function; T-cell-receptor, interleukin-17 and nuclear factor-κB signalling; and T-helper-cell differentiation. Transcriptomic differences were identified in lesional skin at baseline, between subsequent responders and nonresponders. Patients with severe HS who did not respond to adalimumab had enriched complement and B-cell activation pathways at baseline. In addition, logistic regression identified CCL28 in baseline lesional HS skin as a potential biomarker of treatment response.

CONCLUSIONS

This highlights the potential for targeting B-cell and complement pathways in HS treatment and the potential of stratifying patients at baseline to the most suitable treatment based on the skin transcriptome. CCL28 has not previously been identified in HS skin and has potential clinical relevance due to its antimicrobial function and homing of B and T cells at epithelial surfaces. Our results provide data to inform future translational and clinical studies on therapeutics in HS.

Для цитирования: Hambly Roisin, Gatault Solene, Smith Conor M, Iglesias-Martinez Luis F, Kearns Sean, Rea Helen, Marasigan Vivien, Lynam-Loane Kate, Kirthi Shivashini, Hughes Rosalind, Fletcher Jean M, Kolch Walter, Kirby Brian. B-cell and complement signature in severe hidradenitis suppurativa that does not respond to adalimumab.. The British journal of dermatology. 2023. DOI: 10.1093/bjd/ljac007.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.